HAMBURG, Germany, Nov. 18, 2009 (GLOBE NEWSWIRE) -- Evotec (Frankfurt:EVT) (TecDAX), a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to EUR 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection. Evotec will use its drug discovery platform and expertise in progressing this program towards the clinic, particularly making use of its high quality compound library and proprietary fragment-based drug discovery platform.
